IRIS
STAGNO, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.335
NA - Nord America 2.247
AS - Asia 1.812
SA - Sud America 484
Continente sconosciuto - Info sul continente non disponibili 288
AF - Africa 61
OC - Oceania 4
Totale 7.231
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.051
RU - Federazione Russa 1.619
SG - Singapore 725
CN - Cina 390
BR - Brasile 388
IT - Italia 366
HK - Hong Kong 264
VN - Vietnam 146
BD - Bangladesh 93
DE - Germania 84
CA - Canada 71
GB - Regno Unito 65
FR - Francia 63
IN - India 47
MX - Messico 41
AR - Argentina 31
NL - Olanda 25
AT - Austria 23
TR - Turchia 22
ZA - Sudafrica 18
JM - Giamaica 17
ID - Indonesia 16
IQ - Iraq 16
EC - Ecuador 14
HN - Honduras 14
PL - Polonia 14
CO - Colombia 13
FI - Finlandia 13
CR - Costa Rica 12
JP - Giappone 12
TN - Tunisia 11
CL - Cile 10
MY - Malesia 10
PE - Perù 10
PK - Pakistan 10
UA - Ucraina 10
VE - Venezuela 10
MA - Marocco 9
IE - Irlanda 8
PH - Filippine 8
SE - Svezia 8
TT - Trinidad e Tobago 8
EE - Estonia 7
AZ - Azerbaigian 6
ES - Italia 6
SV - El Salvador 6
UZ - Uzbekistan 6
EG - Egitto 5
GT - Guatemala 5
IL - Israele 5
PT - Portogallo 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
DZ - Algeria 4
NI - Nicaragua 4
PA - Panama 4
PR - Porto Rico 4
SA - Arabia Saudita 4
AU - Australia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
JO - Giordania 3
KE - Kenya 3
LT - Lituania 3
NP - Nepal 3
BB - Barbados 2
BE - Belgio 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
BS - Bahamas 2
CI - Costa d'Avorio 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LK - Sri Lanka 2
PY - Paraguay 2
QA - Qatar 2
RO - Romania 2
SN - Senegal 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BJ - Benin 1
BM - Bermuda 1
BO - Bolivia 1
BY - Bielorussia 1
CM - Camerun 1
CU - Cuba 1
CW - ???statistics.table.value.countryCode.CW??? 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
ET - Etiopia 1
GP - Guadalupe 1
HU - Ungheria 1
KH - Cambogia 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
Totale 6.934
Salva come PNG Salva come JPEG
Città #
Moscow 486
Singapore 370
Hong Kong 261
Council Bluffs 250
Ashburn 214
San Jose 206
Beijing 117
Santa Clara 69
Los Angeles 67
Messina 61
Ho Chi Minh City 60
New York 59
Milan 40
São Paulo 37
Dallas 33
Chicago 30
Hanoi 30
Rome 30
Munich 26
North Bergen 26
Atlanta 24
Guangzhou 23
Mexico City 23
Columbus 22
Montreal 21
Nuremberg 21
Brooklyn 20
Orem 19
Frankfurt am Main 18
Houston 17
Vienna 17
Buffalo 16
Catania 15
Naples 15
Phoenix 15
Rio de Janeiro 15
Amsterdam 14
Lauterbourg 14
Redondo Beach 14
Johannesburg 13
Shanghai 13
Porto Alegre 12
Tianjin 12
Boston 11
Palermo 11
Belo Horizonte 10
Brasília 10
Chennai 10
Kingston 10
San Francisco 10
San José 10
Tokyo 10
Warsaw 10
Haiphong 9
Mumbai 9
Seattle 9
Da Nang 8
Denver 8
Philadelphia 8
Poplar 8
Stockholm 8
The Bronx 8
Dhaka 7
Düsseldorf 7
Helsinki 7
Lima 7
London 7
Paris 7
Randolph Township 7
Santo André 7
Toronto 7
Tunis 7
Turin 7
Baghdad 6
Charlotte 6
Las Vegas 6
Nova Iguaçu 6
Quito 6
San Salvador 6
Tashkent 6
The Dalles 6
Baku 5
Bari 5
Bexley 5
Bologna 5
Cleveland 5
Florence 5
Franca 5
Lawrenceville 5
Manchester 5
Natal 5
New Delhi 5
Shenzhen 5
São José dos Campos 5
Ankara 4
Bauru 4
Curitiba 4
Guarulhos 4
Istanbul 4
Jakarta 4
Totale 3.256
Salva come PNG Salva come JPEG
Nome #
Modeling the Bone Marrow Niche in Multiple Myeloma: From 2D Cultures to 3D Systems 178
Influence of Vitamin D and Its Analogues in Type-B Lymphomas 142
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 119
Highlights on the Effects of Non-Coding RNAs in the Osteonecrosis of the Jaw 116
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML 109
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 105
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 102
Bispecific Antibodies and Antibody–Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma 102
Oxidative Stress and Chronic Myeloid Leukemia: A Balance between ROS-Mediated Pro- and Anti-Apoptotic Effects of Tyrosine Kinase Inhibitors 101
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 101
Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment 100
Targeting chronic myeloid leukemia stem/progenitor cells using venetoclax-loaded immunoliposome 98
Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms 94
Decoding Immunodeficiencies with Artificial Intelligence: A New Era of Precision Medicine 92
Biochemical fingerprinting of dried blood serum from chronic lymphocytic leukemia patients by Raman spectroscopy: Towards prognostic classification 92
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 92
DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications 91
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 91
Gut Microbiota Dysbiosis and Dietary Interventions in Non-Hodgkin B-Cell Lymphomas: Implications for Treatment Response 90
Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation 90
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 89
Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey 87
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 87
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: The NEXT-in-CML study 86
Navigating the Landscape of Exosomal microRNAs: Charting Their Pivotal Role as Biomarkers in Hematological Malignancies 85
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 83
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 82
A case of high-risk AML in a patient with advanced systemic mastocytosis 82
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 81
Utilization of Machine Learning in the Prediction, Diagnosis, Prognosis, and Management of Chronic Myeloid Leukemia 78
Bone Marrow Edema and Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia 75
Curcumin and Acute Myeloid Leukemia: Synergistic Effects with Targeted Therapy 74
A Treatment-free Interval Allowed by Ponatinib as Fourth-line Therapy 74
All-trans-retinoic-acid- and growth-factor-mediated induction of alkaline phosphatase activity in freshly isolated chronic myeloid leukemia cells 73
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 72
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells 72
Hematological Malignancies in Older Patients: Focus on the Potential Role of a Geriatric Assessment Management 72
All-trans retinoic acid might also induce apoptosis in freshly isolated chronic myeloid leukemia cells 72
Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea [5] 72
Septic Shock in Hematological Malignancies: Role of Artificial Intelligence in Predicting Outcomes 71
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint 68
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan 64
The Q-LAMP method represents a valid and rapid alternative for the detection of the BCR-ABL1 rearrangement in Philadelphia-positive Leukemias 64
Nilotinib 300 mg twice daily: An academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients 63
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 63
Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up 62
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib 61
Aberrant phenotypic expression of the T-cell-associated antigen CD8 on B-cell chronic lymphocytic leukemia cells 58
Utility of flow cytometry as a screening tool for transplant donors for chronic lymphocytic leukemia 57
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 57
Chk1 inhibition restores inotuzumab ozogamicin citotoxicity in CD22-positive cells expressing mutant p53 57
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib 54
Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population 53
CD34 expression in adult acute lymphoblastic leukemia 52
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 49
Uncommon long-term survival in a patient with chronic myeloid leukemia 49
Cutaneous vasculitis in non Hodgkin's lymphoma 48
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 48
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia 47
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 45
T cell receptor δ-chain gene rearrangement in a novel case of adult NK cell leukemia 45
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network 44
Oxidative Stress and Mitochondrial Dysfunction in Myelodysplastic Syndrome: Roles in Development, Diagnosis, Prognosis, and Treatment 43
null 43
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 43
Dasatinib first-line: Multicentric Italian experience outside clinical trials 43
Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study 42
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib 42
Efficacy of nilotinib in a CML patient expressing the three-way complex variant translocation t(2;9;22) 40
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 39
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database 38
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions 37
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 37
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 36
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 35
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study 35
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients 34
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection 34
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia 34
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 33
Integrated genomic, functional, and prognostic characterization of atypical chronic myeloid leukemia 33
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 33
Efficacy of dasatinib in a very elderly CML patient expressing a rare E13A3 BCR-ABL1 fusion transcript: A case report 33
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report 32
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network 31
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 31
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 31
Infliximab therapy in hematologic malignancies: Handle with care (Comment) 30
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2‑OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 30
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 30
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 29
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 28
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 28
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 27
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 26
Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients 26
Myeloid Derived Suppressor Cells (MDSCs) are increased and exert immunosuppressive activity together with Polymorphonuclear Leukocytes (PMNs) in chronic myeloid leukemia patients 26
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 25
Skeletal Involvement in Systemic Mastocytosis: Pathophysiology, Clinical Management, Standards of Care, and Novel Therapeutic Strategies 25
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 25
Totale 6.147
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.157
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.157
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202429 0 0 0 0 0 0 0 0 0 11 2 16
2024/20251.149 20 0 0 24 54 17 149 137 264 81 126 277
2025/20264.439 146 223 229 314 361 876 361 556 612 346 259 156
2026/20271.614 169 472 343 603 27 0 0 0 0 0 0 0
Totale 7.231